Skip to main content
SpringerLink
Log in

Komplexe Dynamik der Komorbidität Schizophrenie und Cannabiskonsum

  • Living reference work entry
  • First Online:
Handbuch Klinische Psychologie

  • 1751 Accesses

Zusammenfassung

Komorbider Cannabiskonsum ist insbesondere bei jüngeren Patienten mit Schizophrenie sehr häufig. Prominente Erklärungsmodelle umfassen die Affektregulationshypothese, Psychoseinduktion durch spezifische Cannabinoide und gemeinsame Faktoren, die das Auftreten beider Störungen erklären. Die Behandlung ist schwierig. Am ehesten scheinen komplexe Konzepte erfolgreich, die beide Störungen integriert behandeln, sowie Elemente zur Steigerung der Änderungsmotivation, Psychoedukation und Verhaltenstherapie kombinieren. Hinsichtlich der Pharmakotherapie gibt es Medikamente, die sowohl antipsychotisch wirken und gleichzeitig die Suchtkomponente günstig beeinflussen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Literatur

  • Addington, J., & Duchak, V. (1997). Reasons for substance use in schizophrenia. Acta Psychiatrica Scandinavica, 96, 329–333.

    Article  PubMed  Google Scholar 

  • Aderhold, V. (2015). Neuroleptika minimal. dosisabhängige risiken der medikamentösen therapie bei psychosen. PiD, 3, 75–80.

    Google Scholar 

  • Ajdacic-Gross, V., Lauber, C., Warnke, I., Haker, H., Murray, R. M., & Rössler, W. (2007). Changing incidence of psychotic disorders among the young in Zurich. Schizophrenia Research, 95(1−3), 9–18.

    Article  PubMed  Google Scholar 

  • Allebeck, P., Adamsson, C., Engstrom, A., & Rydberg, U. (1993). Cannabis and schizophrenia: A longitudinal study of cases treated in Stockholm County. Acta Psychiatrica Scandinavica, 88, 21–24.

    Article  PubMed  Google Scholar 

  • Andreasson, S., Allebeck, P., Engstrom, A., & Rydberg, U. (1987). Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet, 2, 1483–1486.

    Article  PubMed  Google Scholar 

  • Arseneault, L., Cannon, M., Poulton, R., Murray, R., Caspi, A., & Moffitt, T. E. (2002). Cannabis use in adolescence and risk for adult psychosis: Longitudinal prospective study. BMG, 325, 1212–1213.

    Google Scholar 

  • Barnes, T. R., Mutsatsa, S. H., Hutton, S. B., Watt, H. C., & Joyce, E. M. (2006). Comorbid substance use and age at onset of schizophrenia. The British Journal of Psychiatry, 188, 237–242.

    Article  PubMed  Google Scholar 

  • Bartels, S. J., Drake, R. E., & Wallach, M. A. (1995). Long-term course of substance use disorders among patients with severe mental illness. Psychiatric Services, 46, 248–251.

    Article  PubMed  Google Scholar 

  • Blanchard, J. J., Brown, S. A., Horan, W. P., & Sherwood, A. R. (2000). Substance use disorders in schizophrenia: review, integration, and a proposed model. Clinical Psychology Review, 20, 207–234.

    Article  PubMed  Google Scholar 

  • Blanchard, J. J., Squires, D., Henry, T., Horan, W. P., Bogenschutz, M., Lauriello, J., et al. (1999). Examining an affect regulation model of substance abuse in schizophrenia. The role of traits and coping. The Journal of Nervous and Mental Disease, 187, 72–79.

    Article  PubMed  Google Scholar 

  • Bossong, M. G., & Niesink, R. J. (2010). Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia. Progress in Neurobiology, 92(3), 370–385.

    Article  PubMed  Google Scholar 

  • Bowers, M. B. (1987). The role of drugs in the production of schizophreniform psychoses and related disorders. In H. Y. Meltzer (Hrsg.), Psychopharmacology: The third generation of progress (S. 819–823). New York: Raven Press.

    Google Scholar 

  • Boydell, J., van Os, J., Caspi, A., Kennedy, N., Giouroukou, E., Fearon, P., et al. (2006). Trends in cannabis use prior to first presentation with schizophrenia, in South-East London between 1965 and 1999. Psychological Medicine, 36, 1441–1446.

    Article  PubMed  Google Scholar 

  • Brown, E. S., Nejtek, V. A., Perantie, D. C., Rajan, T. N., & Rush, A. J. (2003). Cocaine and amphetamine use in patients with psychiatric illness: A randomized trial of typical antipsychotic continuation or discontinuation. Journal of Clinical Psychopharmacology, 23, 384–388.

    Article  PubMed  Google Scholar 

  • Brunette, M. F., Mueser, K. T., Xie, H., & Drake, R. E. (1997). Relationships between symptoms of schizophrenia and substance abuse. The Journal of Nervous and Mental Disease, 185, 13–20.

    Article  PubMed  Google Scholar 

  • Caspi, A., Moffitt, T. E., Cannon, M., McClay, J., Murray, R., Harrington, H., et al. (2005). Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: Longitudinal evidence of a gene X environment interaction. Biological Psychiatry, 57(10), 1117–1120.

    Article  PubMed  Google Scholar 

  • Chambers, R. A., Krystal, J. H., & Self, D. W. (2001). A neurobiological basis for substance abuse comorbidity in schizophrenia. Biological Psychiatry, 50, 71–83.

    Article  PubMed  PubMed Central  Google Scholar 

  • Dalmau, A., Bergman, B., & Brismar, B. (1999). Psychotic disorders among inpatients with abuse of cannabis, amphetamine and opiates. Do dopaminergic stimulants facilitate psychiatric illness? European Psychiatry, 14, 366–371.

    Article  PubMed  Google Scholar 

  • Davis, J., Eyre, H., Jacka, F. N., Dean, O., McEven, S., Debnath, M., et al. (2016). A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis. Neuroscience and Biobehavioral Reviews, 65, 185–194.

    Article  PubMed  PubMed Central  Google Scholar 

  • De Marchi, N., De Petrocellis, L., Orlando, P., Daniele, F., Fezza, F., & Di Marzo, V. (2003). Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids in Health and Disease, 19(2), 5.

    Article  Google Scholar 

  • Degenhardt, L., Hall, W., & Lynskey, M. (2003). Testing hypotheses about the relationship between cannabis use and psychosis. Drug and Alcohol Dependence, 71(1), 37–48.

    Article  PubMed  Google Scholar 

  • Dervaux, A., Bayle, F. J., Laqueille, X., Bourdel, M. C., Le Borgne, M. H., Olie, J. P., et al. (2001). Is substance abuse in schizophrenia related to impulsivity, sensation seeking, or anhedonia? The American Journal of Psychiatry, 158, 492–494.

    Article  PubMed  Google Scholar 

  • Drake, R. E., & Mueser, K. T. (2000). Psychosocial approaches to dual diagnosis. Schizophrenia Bulletin, 26, 105–118.

    Article  PubMed  Google Scholar 

  • Drake, R. E., Mueser, K. T., Brunette, M. F., & McHugo, G. J. (2004). A review of treatments for people with severe mental illnesses and co-occurring substance use disorders. Psychiatric Rehabilitation Journal, 27, 360–374.

    Article  PubMed  Google Scholar 

  • Drake, R. E., O’Neal, L., & Wallach, M. A. (2008). A systematic review of psychosocial research on psychosocial interventions for people with co-occurring severe mental and substance use disorders. Journal of Substance Abuse Treatment, 34, 123–138.

    Article  PubMed  Google Scholar 

  • Drake, R. E., Yovetich, N. A., Bebout, R. R., Harris, M., & McHugo, G. J. (1997). Integrated treatment for dually diagnosed homeless adults. The Journal of Nervous and Mental Disease, 185, 298–305.

    Article  PubMed  Google Scholar 

  • Duke, P. J., Pantelis, C., McPhillips, M. A., & Barnes, T. R. (2001). Comorbid non-alcohol substance misuse among people with schizophrenia: Epidemiological study in central London. The British Journal of Psychiatry, 179, 509–513.

    Article  PubMed  Google Scholar 

  • Farrell, M., Boys, A., Bebbington, P., Brugha, T., Coid, J., Lewis, G., et al. (2002). Psychoses and drug dependence: Results of a national survey of prisoners. The British Journal of Psychiatry, 181, 393–398.

    Article  Google Scholar 

  • Ferdinand, R. F., van der Ende, J., Bongers, I., Selten, J. P., Huizink, A., & Verhulst, F. C. (2005). Cannabis-psychosis pathway independent of other types of psychopathology. Schizophrenia Research, 79, 289–295.

    Article  PubMed  Google Scholar 

  • Ferdinand, R. F., Sondeijker, F., van der Ende, J., Selten, J. P., Huizink, A., & Verhulst, F. C. (2005). Cannabis use predicts future psychotic symptoms, and vice versa. Addiction, 100, 612–618.

    Article  PubMed  Google Scholar 

  • Fergusson, D. M., Poulton, R., Smith, P. F., & Boden, J. M. (2006). Cannabis and psychosis. BMJ, 332, 172–175.

    Article  PubMed  PubMed Central  Google Scholar 

  • Foglia, E., Schoeler, T., Klamerus, E., Morgan, K., & Bhattacharyya, S. (2017). Cannabis use and adherence to antipsychotic medication: A systematic review and meta-analyses. Psychological Medicine, 47(10), 1691–1705.

    Article  PubMed  Google Scholar 

  • Gage, S. H., Hickman, M., & Zammit, S. (2016). Association Between Cannabis and Psychosis: Epidemiologic Evidence. Biological Psychiatry, 79, 549–556.

    Article  PubMed  Google Scholar 

  • Gage, S. H., Jones, H. J., Burgess, S., Bowden, J., Davey Smith, G., Zammit, S., & Munafo, M. R. (2017). Assessing causality in associations between cannabis use and schizophrenia risk: A two-sample Mendelian randomization study. Psychological Medicine, 47, 971–980.

    Article  PubMed  Google Scholar 

  • Giannakis, A., & Cordes, J. (2016). Akutbehandlung der Schizophrenie. Psychiatrie und Psychotherapie up2date, 10, 15–27.

    Google Scholar 

  • Giuffrida, A., Leweke, F. M., Gerth, C. W., Schreiber, D., Koethe, D., Faulhaber, J., et al. (2004). Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology, 29(11), 2108–2114.

    Article  PubMed  Google Scholar 

  • Gouzoulis-Mayfrank, E. (2007). Komorbidität Psychose und Sucht – Grundlagen und Praxis. Heidelberg: Steinkopff.

    Google Scholar 

  • Gouzoulis-Mayfrank, E., König, S., Koebke, S., Schnell, T., Schmitz-Buhl, M., & Daumann, J. (2015). Trans-sector integrated treatment in psychosis and addiction – A randomized controlled study of a motivational, cognitive behavioral therapy program under standard hospital treatment conditions. Deutsches Ärzteblatt International, 112(41), 683–691.

    PubMed  PubMed Central  Google Scholar 

  • Granholm, E., Anthenelli, R., Monteiro, R., Sevcik, J., & Stoler, M. (2003). Brief integrated outpatient dual-diagnosis treatment reduces psychiatric hospitalizations. The American Journal on Addictions, 12, 306–313.

    Article  PubMed  Google Scholar 

  • Green, A. I. (2005). Schizophrenia and comorbid substance use disorder: Effects of antipsychotics. The Journal of Clinical Psychiatry, 66(Suppl. 6), 21–26.

    PubMed  Google Scholar 

  • Green, A. I., Tohen, M. F., Hamer, R. M., Strakowski, S. M., Lieberman, J. A., Glick, I., et al. (2004). First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophrenia Research, 66, 125–135.

    Article  PubMed  Google Scholar 

  • Gregg, L., Barrowclough, C., & Haddock, G. (2007). Reasons for increased substance use in psychosis. Clinical Psychology Review, 27(4), 494–510.

    Article  PubMed  Google Scholar 

  • Gupta, S., Hendricks, S., Kenkel, A. M., Bhatia, S. C., & Haffke, E. A. (1996). Relapse in schizophrenia: Is there a relationship to substance abuse? Schizophrenia Research, 20, 153–156.

    Article  PubMed  Google Scholar 

  • Gut-Fayand, A., Dervaux, A., Olie, J. P., Loo, H., Poirier, M. F., & Krebs, M. O. (2001). Substance abuse and suicidality in schizophrenia: A common risk factor linked to impulsivity. Psychiatry Research, 102, 65–72.

    Article  PubMed  Google Scholar 

  • Hambrecht, M., & Hafner, H. (1996). Substance abuse and the onset of schizophrenia. Biological Psychiatry, 40, 1155–1163.

    Article  PubMed  Google Scholar 

  • Hamilton, I. (2017). Cannabis, psychosis and schizophrenia: Unravelling a complex interaction. Addiction, 112(9), 1653–1657.

    Article  PubMed  Google Scholar 

  • Hanna, R. C., Shalvoy, A., Cullum, C. M., Ivleva, E. I., Keshavan, M., Pearlson, et al. (2016). Cognitive function in individuals with psychosis: Moderation by adolescent cannabis use. Schizophrenia Bulletin, 42, 1496–1503.

    Article  PubMed  PubMed Central  Google Scholar 

  • Haywood, T. W., Kravitz, H. M., Grossman, L. S., Cavanaugh, J., Davis, J. M., & Lewis, D. A. (1995). Predicting the „revolving door“ phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. The American Journal of Psychiatry, 152, 856–861.

    Article  PubMed  Google Scholar 

  • Henquet, C., Krabbendam, L., Spauwen, J., Kaplan, C., Lieb, R., Wittchen, H. U., et al. (2005). Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ, 330, 11.

    Article  PubMed  PubMed Central  Google Scholar 

  • Hickmann, M., Vickerman, P., Macleod, J., Kirkbride, J., & Jones, P. (2007). Cannabis and schizophrenia: model projections of the impact of the rise in cannabis use on historical and future trends in schizophrenia in England and Wales. Addiction, 102, 597–606.

    Article  Google Scholar 

  • Hiemstra, M., Nelemans, S. A., Branje, S., van Eijk, K. R., Hottenga, J. J., Vinkers, C. H., et al. (2018). Genetic vulnerability to schizophrenia is associated with cannabis use patterns during adolescence. Drug and Alcohol Dependence, 190, 143–150.

    Article  PubMed  Google Scholar 

  • Hosak, L. (2013). New findings in the genetics of schizophrenia. World J Psychiatry, 3, 57–61.

    Article  PubMed  PubMed Central  Google Scholar 

  • Hunt, G. E., Large, M. M., Cleary, M., Lai, H. M. X., & Saunders, J. B. (2018). Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990–2017: Systematic review and meta-analysis. Drug and Alcohol Dependence, 191, 234–258.

    Article  PubMed  Google Scholar 

  • Johns, A. (2001). Psychiatric effects of cannabis. The British Journal of Psychiatry, 178, 116–122.

    Article  PubMed  Google Scholar 

  • Kensche, M., Bromand, Z., & Kienast, T. (2014). Evidenzbasierte Psychotherapie bei Patienten mit Substanzabhängigkeit und psychischer Komorbidität. PSYCHup2date, 8, 9–18.

    Google Scholar 

  • Khantzian, E. J. (1985). The self-medication hypothesis of addictive disorders: Focus on heroin and cocaine dependence. The American Journal of Psychiatry, 142, 1259–1264.

    Article  PubMed  Google Scholar 

  • Khantzian, E. J. (1997). The self-medication hypothesis of substance use disorders: A reconsideration and recent applications. Harvard Review of Psychiatry, 4, 231–244.

    Article  PubMed  Google Scholar 

  • Kirkbride, J. B., Fearon, P., Morgan, C., et al. (2006). Heterogeneity in incidence rates of schizophrenia and other psychotic syndromes: Findings from the 3-center AeSOP study. Archives of General Psychiatry, 63, 250–258.

    Article  PubMed  Google Scholar 

  • Klingenberg, S., & Bechdolf, A. (2013). Schizophrenie – psychosoziale Therapie (ICD-10 F2). In U. Voderholzer & F. Hohagen (Hrsg.), Therapie psychischer Erkrankungen. State of the art 2013/2014 (S. 113–132). Urban & Fischer: München.

    Google Scholar 

  • Koskinen, J., Löhönen, J., Koponen, H., Isohanni, M., & Miettunen, J. (2010). Rate of cannabis use disorders in clinical samples of patients with schizophrenia: A meta-analysis. Schizophrenia Bulletin, 36(6), 1115–1130.

    Article  PubMed  Google Scholar 

  • Ksir, C., & Hart, C. L. (2016). Cannabis and psychosis: A critical overview of the relationship. Current Psychiatry Reports, 18(2), 12.

    Article  PubMed  Google Scholar 

  • Linszen, D., & van Amelsvoort, T. (2007). Cannabis and psychosis: An update on course and biological plausible mechanisms. Current Opinion in Psychiatry, 20, 116–120.

    Article  PubMed  Google Scholar 

  • Lubman, D. I., Cheetham, A., & Yücel, M. (2015). Cannabis and adolescent brain development. Pharmacology & Therapeutics, 148, 1–16.

    Article  Google Scholar 

  • Lubman, D. I., King, J. A., & Castle, D. J. (2010). Treating comorbid substance use disorders in schizophrenia. International Review of Psychiatry, 22(2), 191–201.

    Article  PubMed  Google Scholar 

  • Mallet, J., Ramoz, N., Le Strat, Y., Gorwood, P., & Dubertret, C. (2017). Heavy cannabis use prior psychosis in schizophrenia: Clinical, cognitive and neurological evidences for a new endophenotype? European Archives of Psychiatry and Clinical Neuroscience, 267(7), 629–638.

    Article  PubMed  Google Scholar 

  • Mané, A., Bergé, D., Penzol, M. J., Parellada, M., Bioque, M., Lobo, A., et al. (2017). Cannabis use, COMT, BDNF and age at first-episode psychosis. Psychiatry Research, 250, 38–43.

    Article  PubMed  Google Scholar 

  • Mechoulam, R., & Parker, L. A. (2013). The endocannabinoid system and the brain. Annual Review of Psychology, 64, 21–47.

    Article  PubMed  Google Scholar 

  • Meier, M. H., Caspi, A., Ambler, A., Harrington, H., Houts, R., Keefe, R. S., et al. (2012). Persistent cannabis users show neuropsychological decline from childhood to midlife. Proceedings of the National Academy of Sciences of the United States of America, 109(40), 2657–2664.

    Article  Google Scholar 

  • Mollon, J., & Reichenberg, A. (2018). Cognitive development prior to onset of psychosis. Psychological Medicine, 48(3), 392–403.

    Article  PubMed  Google Scholar 

  • Moulin, V., Baumann, P., Gholamrezaee, M., Alameda, L., Palix, J., Gasser, J., & Conus, P. (2018). Cannabis, a significant risk factor for violent behavior in the early phase psychosis. Two patterns of interaction of factors increase the risk of violent behavior: Cannabis use disorder and impulsivity; cannabis use disorder, lack of insight and treatment adherence. Frontiers in Psychiatry, 9, 294.

    Article  PubMed  PubMed Central  Google Scholar 

  • Mueser, K. T., Drake, R. E., & Wallach, M. A. (1998). Dual diagnosis: A review of etiological theories. Addictive Behaviors, 23, 717–734.

    Article  PubMed  Google Scholar 

  • Mueser, K. T., Yarnold, P. R., & Bellack, A. S. (1992). Diagnostic and demographic correlates of substance abuse in schizophrenia and major affective disorder. Acta Psychiatrica Scandinavica, 85, 48–55.

    Article  PubMed  Google Scholar 

  • Mueser, K. T., Yarnold, P. R., Levinson, D. F., Singh, H., Bellack, A. S., Kee, K., et al. (1990). Prevalence of substance abuse in schizophrenia: Demographic and clinical correlates. Schizophrenia Bulletin, 16, 31–56.

    Article  PubMed  Google Scholar 

  • Mueser, K. T., Yarnold, P. R., & Rosemberg, S. D. (2000). Substance use disorder in hospitalized severely mentally ill psychiatric patients: Prevalence, correlates, and subgroups. Schizophrenia Bulletin, 26, 179–192.

    Article  PubMed  Google Scholar 

  • Murray, R. M., Arseneault, L., Caspi, A., Moffitt, T., Cannon, M., Boydell, J., & Thirtalli, J. (2006). Adolescent cannabis use and later psychosis. Schizophrenia Research, 81(Suppl), 10–11.

    Google Scholar 

  • Petrakis, I. L., Nich, C., & Ralevski, E. (2006). Psychotic spectrum disorders and alcohol abuse: A review of pharmacotherapeutic strategies and a report on the effectiveness of Naltrexone and Disulfiram. Schizophrenia Bulletin, 32, 644–654.

    Article  PubMed  PubMed Central  Google Scholar 

  • Petrakis, I. L., O’Malley, S., Rounsaville, B., Poling, J., Hugh-Strong, C., & Krystal, J. H. (2004). Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology, 172, 291–297.

    Article  PubMed  Google Scholar 

  • Petrakis, I. L., Poling, J., Levinson, C., Nich, C., Carroll, K., & Rounsaville, B. (2005). Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders. Biological Psychiatry, 57, 1128–1137.

    Article  PubMed  Google Scholar 

  • Poole, R., & Brabbins, C. (1996). Drug induced psychosis. The British Journal of Psychiatry, 168, 135–138.

    Article  PubMed  Google Scholar 

  • Regier, D. A., Farmer, M. E., Rae, D. S., Locke, B. Z., Keith, S. J., Judd, L. L., et al. (1990). Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA, 264, 2511–2518.

    Article  PubMed  Google Scholar 

  • Ripke, S., Neale, B. M., Corvin, A., Walters, J. T. R., Farh, K., Holmans, P. A., Schizophrenia Working Group of the Psychiatric Genomics Consortium, et al. (2014). Biological insights from 108 schizophrenia-associated genetic loci. Nature, 511(7510), 421–427.

    Article  PubMed Central  Google Scholar 

  • Sami, M. B., & Bhattacharyya, S. (2018). Are cannabis-using and non-using patients different groups? Towards understanding the neurobiology of cannabis use in psychotic disorders. Journal of Psychopharmacology (Oxford), 32(8), 825–849.

    Article  Google Scholar 

  • Sami, M., Notley, C., Kouimtsidis, C., Lynskey, M., & Bhattacharyya, S. (2019). Psychotic-like experiences with cannabis use predict cannabis cessation and desire to quit: A cannabis discontinuationhypothesis. Psychological Medicine, 49(1), 103–112.

    Article  PubMed  Google Scholar 

  • Scharfetter, C. (2010). Allgemeine psychopathologie. Stuttgart: Thieme.

    Google Scholar 

  • Schneier, F. R., & Siris, S. G. (1987). A review of psychoactive substance use and abuse in schizophrenia. Patterns of drug choice. The Journal of Nervous and Mental Disease, 175, 641–652.

    Article  PubMed  Google Scholar 

  • Schnell, T. (2013). Klinische Prognose schizophrener Patienten mit Cannabisabhängigkeit zwischen Nihilismus und Hoffnung. Nervenarzt, 85(9), 1084–1092.

    Article  Google Scholar 

  • Schnell, T. (2017). Aufrechterhaltende Dynamik und klinische Prognose komorbider Schizophrenie und Cannabisabhängigkeit. Habilitationsschrift, Martin-Luther-Universität Halle-Wittenberg, Institut für Psychologie.

    Google Scholar 

  • Schnell, T., & Gouzoulis-Mayfrank, E. (2010). Therapie suchtkranker Schizophrener. Suchtmed, 12(5), 1–10.

    Google Scholar 

  • Schnell, T., Neisius, K., Daumann, J., & Gouzoulis-Mayfrank, E. (2010). Prevalence of psychosis/substance use comorbidity. Clinical-epidemiological findings from different treatment-settings in a large German city. Nervenarzt, 81(3), 32–38.

    Article  Google Scholar 

  • Schnell, T., Kleinmann, A., Gouzoulis-Mayfrank, E., Wagner, D., Daumann, J., & Becker, B. (2012). Increased grey matter density in patients with schizophrenia and cannabis use. A voxel-based morphometric study using DARTEL. Schizophrenia Research, 138(2-3), 183–187.

    Article  PubMed  Google Scholar 

  • Schnell, T., von Katte, S., & Gast, U. (2015). Bereitschaft niedergelassener Therapeuten zur Behandlung von Patienten mit komplexen posttraumatischen und dissoziativen Störungen. Fortschritte der Neurologie-Psychiatrie, 83, 1–6.

    Google Scholar 

  • Schoeler, T., Monk, A., Sami, M. B., Klamerus, E., Foglia, E., Brown, R., et al. (2016). Continued versus discontinued cannabis use in patients with psychosis: A systematic review and meta-analysis. The Lancet Psychiatry, 3, 215–225.

    Article  PubMed  Google Scholar 

  • Schofield, D., Tennant, C., Nash, L., Degenhardt, L., Cornish, A., Hobbs, C., et al. (2006). Reasons for cannabis use in psychosis. The Australian and New Zealand Journal of Psychiatry, 40, 570–574.

    Article  PubMed  Google Scholar 

  • Sekar, A., Bialas, A. R., de Rivera, H., Davis, A., Hammond, T. R., Kamitaki, N., et al. (2016). Schizophrenia risk from complex variation of complement component 4. Nature, 530(7589), 177–183.

    Article  PubMed  PubMed Central  Google Scholar 

  • Stefanis, N. C., Dragovic, M., Power, B. D., Jablensky, A., Castle, D., & Morgan, V. A. (2013). Age at initiation of cannabis use predicts age at onset of psychosis: The 7- to 8-year trend. Schizophrenia Bulletin, 39(2), 251–254.

    Article  PubMed  PubMed Central  Google Scholar 

  • Swofford, C. D., Kasckow, J. W., Scheller-Gilkey, G., & Inderbitzin, L. B. (1996). Substance use: A powerful predictor of relapse in schizophrenia. Schizophrenia Research, 20, 145–151.

    Article  PubMed  Google Scholar 

  • Van Os, J., Bak, M., Hanssen, M., Bijl, R. V., De Graaf, R., & Verdoux, H. (2002). Cannabis use and psychosis: A longitudinal population-based study. American Journal of Epidemiology, 156, 319–327.

    Article  PubMed  Google Scholar 

  • Vauth, R. (2012). Psychotherapie der Schizophrenie. Psychiatrie und Psychotherapie up2date, 6, 345–360.

    Google Scholar 

  • Veen, N. D., Selten, J. P., Feller, W. G., Hoek, H. W., & Kahn, R. S. (2004). Cannabis use and age at onset of schizophrenia. The American Journal of Psychiatry, 161, 501–506.

    Article  PubMed  Google Scholar 

  • Verweij, K. J. H., Abdellaoui, A., Nivard, M. G., Cort, A. S., Ligthart, L., Draisma, H. H. M., et al. (2017). Short communication: Genetic association between schizophrenia and cannabis use. Drug and Alcohol Dependence, 171, 117–121.

    Article  PubMed  PubMed Central  Google Scholar 

  • Weiser, M., & Noy, S. (2005). Interpreting the association between cannabis use and increased risk for schizophrenia. Dialogues in Clinical Neuroscience, 7(1), 81–85.

    PubMed  PubMed Central  Google Scholar 

  • Wobrock, T., & Soyka, M. (2008). Pharmacotherapy of schizophrenia with comorbid substance use disorder – Reviewing the evidence and clinical recommendations. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 32(6), 1375–1385.

    Article  Google Scholar 

  • Yücel, M., Solowij, N., & Respondek, C. (2008). Regional brain abnormalities associated with long-term heavy cannabis use. Archives of General Psychiatry, 65(6), 694–701.

    Article  PubMed  Google Scholar 

  • Zammit, S., Allebeck, P., Andreasson, S., Lundberg, I., & Lewis, G. (2002). Self-reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: Historical cohort study. BMJ, 325, 1199.

    Article  PubMed  PubMed Central  Google Scholar 

  • Zimmet, S. V., Strous, R. D., Burgess, E. S., Kohnstamm, S., & Green, A. I. (2000). Effects of Clozapine on substance use in patients with schizophrenia and schizoaffective disorder: A retrospective survey. Journal of Clinical Psychopharmacology, 20, 94–98.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Fakultät Gesundheit, Medical School Hamburg, Hamburg, Deutschland

    Thomas Schnell

Authors
  1. Thomas Schnell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas Schnell .

Editor information

Editors and Affiliations

  1. Klinische Psychologie, Medical School Hamburg, Hamburg, Germany

    Thomas Schnell

  2. Asklepios Fachklinikum, Göttingen, Niedersachsen, Germany

    Knut Schnell

Section Editor information

  1. Klinische Psychologie, Medical School Hamburg, Hamburg, Germany

    Thomas Schnell

  2. Psychiatrie und Psychotherapie, LVR-Klinik Köln, Köln, Germany

    Euphrosyne Gouzoulis-Mayfrank

  3. Technische Universität Dresden, Dresden, Germany

    Katja Beesdo-Baum

  4. Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany

    Ingo Schäfer

  5. Medical School Hamburg, Hamburg, Germany

    Erich Kasten

  6. HSD Hochschule Döpfer, Köln, Germany

    Janine Trunk

  7. Institut für Psychologische Psychotherapie IPP, Bochum, Germany

    Rainer Sachse

  8. Allgemeine Psychiatrie, LVR-Klinikum Essen, Essen, Germany

    Christian Mette

  9. Medical School Hamburg, Hamburg, Germany

    Silke Wiegand-Grefe

  10. LVR-Klinik Köln, Köln, Deutschland

    Euphrosyne Gouzoulis-Mayfrank

  11. Fakultät Gesundheit, Medical School Hamburg, Hamburg, Deutschland

    Thomas Schnell

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Schnell, T. (2019). Komplexe Dynamik der Komorbidität Schizophrenie und Cannabiskonsum. In: Schnell, T., Schnell, K. (eds) Handbuch Klinische Psychologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-45995-9_20-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-45995-9_20-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-45995-9

  • Online ISBN: 978-3-662-45995-9

  • eBook Packages: Springer Referenz Psychologie

Publish with us

Policies and ethics

Search

Navigation